OA12256A - Sodium-hydrogen exchanger type 1 inhibitor (NHE-1). - Google Patents

Sodium-hydrogen exchanger type 1 inhibitor (NHE-1). Download PDF

Info

Publication number
OA12256A
OA12256A OA1200200331A OA1200200331A OA12256A OA 12256 A OA12256 A OA 12256A OA 1200200331 A OA1200200331 A OA 1200200331A OA 1200200331 A OA1200200331 A OA 1200200331A OA 12256 A OA12256 A OA 12256A
Authority
OA
OAPI
Prior art keywords
compound
tissue
recited
prodrug
pharmaceutically acceptable
Prior art date
Application number
OA1200200331A
Other languages
English (en)
Inventor
Weichao George Chen
Eric David Cox
Angel Guzman-Perez
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA12256A publication Critical patent/OA12256A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200200331A 2000-04-28 2001-02-28 Sodium-hydrogen exchanger type 1 inhibitor (NHE-1). OA12256A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
OA12256A true OA12256A (en) 2003-11-06

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200331A OA12256A (en) 2000-04-28 2001-02-28 Sodium-hydrogen exchanger type 1 inhibitor (NHE-1).

Country Status (40)

Country Link
EP (1) EP1276737A1 (es)
JP (1) JP2003531900A (es)
KR (1) KR20020093079A (es)
CN (1) CN1225466C (es)
AP (1) AP2002002651A0 (es)
AR (1) AR028375A1 (es)
AU (1) AU2001235896A1 (es)
BG (1) BG107139A (es)
BR (1) BR0110268A (es)
CA (1) CA2407535A1 (es)
CO (1) CO5221125A1 (es)
CR (1) CR6797A (es)
CZ (1) CZ20023408A3 (es)
DZ (1) DZ3310A1 (es)
EA (1) EA004882B1 (es)
EE (1) EE200200615A (es)
GT (1) GT200100064A (es)
HN (1) HN2001000042A (es)
HR (1) HRP20020851A2 (es)
HU (1) HUP0300651A2 (es)
IL (1) IL152075A0 (es)
IS (2) IS6567A (es)
MA (1) MA26897A1 (es)
MX (1) MXPA02010600A (es)
MY (1) MY133842A (es)
NO (1) NO20025132L (es)
NZ (1) NZ521348A (es)
OA (1) OA12256A (es)
PA (1) PA8513301A1 (es)
PE (1) PE20011270A1 (es)
PL (1) PL357765A1 (es)
SK (1) SK14872002A3 (es)
SV (1) SV2002000418A (es)
TN (1) TNSN01065A1 (es)
TR (1) TR200202439T2 (es)
UA (1) UA73348C2 (es)
UY (1) UY26680A1 (es)
WO (1) WO2001083470A1 (es)
YU (1) YU79602A (es)
ZA (1) ZA200208605B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU51903A (sh) * 2001-01-31 2006-05-25 Pfizer Products Inc. Enolati inhibitora izmene natrijum-vodonik tipa-1
CA2469305A1 (en) * 2001-12-19 2003-06-26 Frank Robert Busch Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ES2220185B1 (es) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas Nuevo peptido inhibidor del intercambiador na+/h+ (pinhe), y sus aplicaciones.
PL378111A1 (pl) * 2003-02-14 2006-03-06 Smithkline Beecham Corporation Nowe związki
RU2518741C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ГАЛОГЕНИДЫ 1-ДИАЛКИЛАМИНОЭТИЛ-3-[ЗАМЕЩЕННЫЙ(ДИЗАМЕЩЕННЫЙ) ФЕНАЦИЛ]-2-АМИНОБЕНЗИМИДАЗОЛИЯ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030083004A (ko) * 1998-02-27 2003-10-23 화이자 프로덕츠 인크. 허혈 치료용 n-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체

Also Published As

Publication number Publication date
CA2407535A1 (en) 2001-11-08
ZA200208605B (en) 2003-10-24
DZ3310A1 (fr) 2001-11-07
BG107139A (bg) 2003-07-31
MY133842A (en) 2007-11-30
HN2001000042A (es) 2001-07-09
AP2002002651A0 (en) 2002-12-31
NO20025132D0 (no) 2002-10-25
EE200200615A (et) 2004-04-15
SV2002000418A (es) 2002-07-03
UY26680A1 (es) 2001-12-28
CR6797A (es) 2004-05-17
MA26897A1 (fr) 2004-12-20
YU79602A (en) 2006-05-25
CN1225466C (zh) 2005-11-02
JP2003531900A (ja) 2003-10-28
AR028375A1 (es) 2003-05-07
PL357765A1 (en) 2004-07-26
EA004882B1 (ru) 2004-08-26
EA200201023A1 (ru) 2003-02-27
CZ20023408A3 (cs) 2004-01-14
BR0110268A (pt) 2003-12-30
PA8513301A1 (es) 2003-09-05
UA73348C2 (en) 2005-07-15
PE20011270A1 (es) 2001-12-12
IL152075A0 (en) 2003-05-29
NZ521348A (en) 2004-09-24
IS6567A (is) 2002-09-24
HUP0300651A2 (hu) 2003-07-28
TR200202439T2 (tr) 2003-02-21
HRP20020851A2 (en) 2005-02-28
EP1276737A1 (en) 2003-01-22
TNSN01065A1 (fr) 2005-11-10
AU2001235896A1 (en) 2001-11-12
CO5221125A1 (es) 2002-11-28
IS6588A (is) 2002-10-21
NO20025132L (no) 2002-12-12
MXPA02010600A (es) 2003-03-10
WO2001083470A1 (en) 2001-11-08
SK14872002A3 (sk) 2004-03-02
CN1426404A (zh) 2003-06-25
GT200100064A (es) 2002-03-22
KR20020093079A (ko) 2002-12-12

Similar Documents

Publication Publication Date Title
KR20010080596A (ko) 치환된 벤즈이미다졸 및 parp 억제제로서 그의 용도
US6645966B2 (en) Treatment of malaria with farnesyl protein transferase inhibitors
CN111548345B (zh) 一类苯并咪唑类衍生物及其制备方法和应用
KR20150125716A (ko) 새로운 술폰아미드 trpa1 수용체 길항제
US4868193A (en) Styryl tetrazoles and anti-allergic use thereof
OA12256A (en) Sodium-hydrogen exchanger type 1 inhibitor (NHE-1).
EP0266989A2 (en) Dihydropyridine anti-allergic and anti-inflammatory agents
US6852733B2 (en) Sodium-hydrogen exchanger type 1 inhibitor
KR100464526B1 (ko) 나트륨-수소 교환체 타입 1 억제제 결정
JPS6335562A (ja) カルボスチリル誘導体
TWI221152B (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
KR101725292B1 (ko) 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체
JPH0770083A (ja) イミダゾール誘導体を有効成分とする血圧降下剤
JPH0676323B2 (ja) 抗潰瘍剤
JPS6122068A (ja) オキシインド−ル誘導体
JPH07116157B2 (ja) カルボスチリル誘導体